A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

医学 恶心 内科学 不利影响 胃肠病学 实体瘤疗效评价标准 酪氨酸激酶抑制剂 肺癌 队列 免疫组织化学 肿瘤科 呕吐 便秘 癌症 进行性疾病 化疗
作者
Eric Angevin,Gianluca Spitaleri,Jordi Rodón,Katia Dotti,Nicolás Isambert,Stefania Salvagni,Víctor Moreno,Sylvie Assadourian,Corinne Gomez,Marzia Harnois,Antoine Hollebecque,Analía Azaro,Alice Hervieu,Karim Rihawi,Filippo de Marinis
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:87: 131-139 被引量:37
标识
DOI:10.1016/j.ejca.2017.10.016
摘要

PurposeDysregulated MET signalling is implicated in oncogenesis. The safety and preliminary efficacy of a highly selective MET kinase inhibitor (SAR125844) was investigated in patients with advanced solid tumours and MET dysregulation.MethodsThis was a phase I dose-escalation (3 + 3 design [50–740 mg/m2]) and dose-expansion study. In the dose escalation, patients had high total MET (t-MET) expression by immunohistochemistry (IHC) or MET amplification by fluorescence in situ hybridisation. In the dose expansion, patients had MET amplification (including a subset of patients with non-small cell lung cancer [NSCLC]) or phosphorylated-MET (p-MET) expression (IHC). Objectives were determination of maximum tolerated dose (MTD) of once-weekly intravenous SAR125844 based on dose-limiting toxicities; safety and pharmacokinetic profile; preliminary efficacy of SAR125844 MTD in the expansion cohort.ResultsIn total, 72 patients were enrolled: dose escalation, N = 33; dose expansion, N = 39; 570 mg/m2 was established as the MTD. Most frequent treatment-emergent adverse events (AEs) were asthenia/fatigue (58.3%), nausea (31.9%), and abdominal pain, constipation, and dyspnea (27.8% for each); 58.3% of patients reported grade 3 AEs (19.4% were treatment related). Of the 29 evaluable patients with MET amplification treated at 570 mg/m2, five achieved a partial response, including four of 22 with NSCLC; 17 patients had stable disease. No response was observed in patients with high p-MET solid tumours. There was no correlation between tumour response and t-MET status or MET gene copy number.ConclusionThe MTD of once-weekly SAR125844 was 570 mg/m2; SAR125844 was well tolerated, with significant antitumour activity in patients with MET-amplified NSCLC.Clinical trial registration number: NCT01391533
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava应助wjxcl采纳,获得10
刚刚
闪闪如南发布了新的文献求助10
刚刚
深情安青应助一二不休采纳,获得10
1秒前
3秒前
123完成签到,获得积分10
3秒前
不扯先生完成签到,获得积分10
4秒前
柳絮完成签到,获得积分20
5秒前
lll完成签到,获得积分10
5秒前
sdl完成签到,获得积分10
5秒前
Orange应助孟婆的碗采纳,获得10
6秒前
zhangmy1989发布了新的文献求助30
6秒前
6秒前
清秀的不言完成签到 ,获得积分10
6秒前
杂化轨道退役研究员完成签到,获得积分10
6秒前
FashionBoy应助tanglu采纳,获得10
7秒前
8秒前
闪闪如南完成签到,获得积分10
9秒前
wjxcl完成签到,获得积分10
10秒前
10秒前
10秒前
12233完成签到,获得积分10
11秒前
11秒前
洪武完成签到,获得积分20
11秒前
12秒前
Yuantian发布了新的文献求助10
13秒前
传奇3应助浪花淘尽英雄采纳,获得10
14秒前
流川枫完成签到,获得积分10
14秒前
赘婿应助leo采纳,获得10
14秒前
追寻夏烟完成签到 ,获得积分10
15秒前
闪闪寒云完成签到 ,获得积分10
15秒前
13633501455完成签到 ,获得积分10
16秒前
阿里完成签到,获得积分10
16秒前
蓁蓁发布了新的文献求助10
17秒前
科研通AI5应助加百莉采纳,获得10
17秒前
WELXCNK完成签到,获得积分10
18秒前
GG波波完成签到,获得积分10
19秒前
susu完成签到 ,获得积分10
19秒前
20秒前
20秒前
海阔天空发布了新的文献求助10
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048